Epilepsy is a heterogeneous condition requiring individualized treatment, based largely on a patient’s seizure syndrome and seizure type. Epilepsy patients also differ widely in their responses to treatment with antiepileptic drugs (AEDs) and often are treatment-refractory. As a result, neurologists must consider many factors when selecting among the numerous first-, second-, and third-generation AEDs currently available, and make adjustments—in dosing, or by adding and switching—throughout a patients’ disease course to achieve optimal seizure control. Understanding the many decision points neurologists face in the treatment of epilepsy provides important context about the complex market that developers of investigational AEDs will enter.

How is epilepsy being treated in the United States today, and what are the factors behind those treatment decisions? The Epilepsy Current Treatment Overview provides a synopsis of current treatment goals, key therapies, and medical practice in the G7 markets. The detailed, expanded analysis in Epilepsy Current Treatment (US) offers a snapshot of how U.S. neurologists are currently managing their epilepsy patients as well as insight into the factors driving such prescribing habits. This new Current Treatment offering provides deep insights, with real-world evidence wherever possible.

Table of contents

  • Epilepsy - Current Treatment - Detailed, Expanded Analysis (US)

Author(s): Bethany Christmann, PhD

Bethany Christmann, Ph.D., has been with DRG since 2015, and is a Senior Business Insights Analyst with the Central Nervous System/Ophthalmology team. In this role, she covers the neurology space, specializing in Parkinson’s disease and epilepsy; she provides expert insight and authors primary market research and forecasting content focused on these and other neurology indications. Prior to joining DRG, Bethany earned her Ph.D. in neuroscience from Brandeis University, where she studied the cellular interactions involved in memory consolidation and their link to sleep behavior.


Related Reports

Epilepsy - Landscape & Forecast - Disease Landscape & Forecast

Epilepsy, which afflicts approximately 4.7 million people in the major markets according to DRG epidemiology, is a heterogeneous condition requiri...

View Details

Epilepsy - Access & Reimbursement - Detailed, Expanded Analysis (US)

Despite the large number of currently marketed antiepileptic drugs (AEDs), important unmet needs remain for new therapies to treat refractory epilepsy and se...

View Details

Epilepsy - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US) Total

Epilepsy is a heterogeneous condition requiring individualized treatment—especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selectin...

View Details

Epilepsy | Disease Landscape and Forecast | G7 | 2019

Epilepsy, which afflicts approximately 4.7 million people in the G7 according to DRGepidemiology, is a heterogeneous condition r...

View Details